Polaris AI Pharma KRX:041910KOSDAQ
폴라리스AI파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Polaris AI Pharma reported revenue of ₩14.7bn, up 6.5% year on year, and operating profit of ₩779m. Polaris AI Pharma (폴라리스AI파마) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Polaris AI Pharma quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩14.7bn | +6.5% | ₩779m margin 5.3% | ₩6.7bn |
| Q1 2026 | ₩13.7bn | +7.3% | ₩606m margin 4.4% | ₩3.7bn |
| Q4 2025 derived | ₩14.3bn | -12.2% | −₩392m margin −2.7% | ₩379m |
| Q3 2025 | ₩14.7bn | +4.0% | ₩1.6bn margin 10.7% | ₩3.5bn |
| Q2 2025 | ₩13.8bn | -8.1% | ₩1.3bn margin 9.2% | ₩1.3bn |
| Q1 2025 | ₩12.8bn | -10.0% | ₩736m margin 5.8% | ₩985m |
| Q4 2024 derived | ₩16.3bn | -0.3% | −₩1.1bn margin −6.8% | ₩1.3bn |
| Q3 2024 | ₩14.1bn | -3.9% | ₩779m margin 5.5% | ₩1.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Polaris AI Pharma top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Polaris AI Pharma news Korean headlines
No articles yet.